| Market Cap | 136.26Cr 121.75Cr 113.59Cr 103.18Cr 194.32Cr 13TCr 195.77Cr 1.37TCr 533.29Cr 6.7TCr 511.56Cr 500.5Cr 22TCr | P/E 2026 * |
-4.98x | P/E 2027 * | -3.93x |
|---|---|---|---|---|---|
| Enterprise Value | 127.46Cr 113.89Cr 106.25Cr 97Cr 181.77Cr 12TCr 183.13Cr 1.28TCr 498.84Cr 6.27TCr 478.52Cr 468.17Cr 20TCr | EV / Sales 2026 * |
30.4x | EV / Sales 2027 * | 20.2x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 136.26Cr | |
| +4.16% | +4.16% | +49.37% | +94.17% | 7.47TCr | |
| +0.46% | -1.16% | +23.36% | +79.34% | 5.88TCr | |
| +0.17% | -1.16% | +3.59% | +34.55% | 4.84TCr | |
| +0.50% | -1.77% | +331.24% | +702.20% | 4.28TCr | |
| -0.72% | -4.04% | +25.90% | +29.94% | 4.28TCr | |
| +0.34% | -0.34% | +5.66% | +109.35% | 4.12TCr | |
| -0.11% | +1.96% | +9.19% | +52.66% | 3.11TCr | |
| -2.07% | +1.16% | +35.00% | +26.28% | 3.03TCr | |
| -0.50% | -3.37% | -9.42% | -14.35% | 2.4TCr | |
| Average | +0.06% | -0.25% | +52.65% | +123.79% | 4.38TCr | |
| Weighted average by Cap. | +0.55% | -0.54% | +55.51% | +130.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.19Cr 3.74Cr 3.49Cr 3.17Cr 5.97Cr 405.1Cr 6.02Cr 42Cr 16Cr 206.02Cr 16Cr 15Cr 662.31Cr | 5.7Cr 5.09Cr 4.75Cr 4.32Cr 8.13Cr 551.36Cr 8.19Cr 57Cr 22Cr 280.4Cr 21Cr 21Cr 901.42Cr |
| Net income | -24Cr -22Cr -20Cr -19Cr -35Cr -2.37TCr -35Cr -245.1Cr -96Cr -1.2TCr -92Cr -90Cr -3.87TCr | -35Cr -32Cr -29Cr -27Cr -50Cr -3.42TCr -51Cr -354.36Cr -138.44Cr -1.74TCr -132.8Cr -129.93Cr -5.59TCr |
| Net Debt | -8.8Cr -7.86Cr -7.34Cr -6.66Cr -13Cr -851.45Cr -13Cr -88Cr -34Cr -433.02Cr -33Cr -32Cr -1.39TCr | -21Cr -19Cr -18Cr -16Cr -30Cr -2.04TCr -30Cr -210.74Cr -82Cr -1.03TCr -79Cr -77Cr -3.33TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
